Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality (Q41951871)

14 October 2017

Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality (English)

1 reference

14 October 2017

8

Peter S Nelson

1 reference

14 October 2017

E Sophie Spencer

1

1 reference

14 October 2017

Richard B Johnston

2

1 reference

14 October 2017

Ryan R Gordon

3

1 reference

14 October 2017

Jared M Lucas

4

1 reference

14 October 2017

Cigdem Himmetoglu Ussakli

5

1 reference

14 October 2017

Antonio Hurtado-Coll

6

1 reference

14 October 2017

Shiv Srivastava

7

1 reference

14 October 2017

Christopher R Porter

9

1 reference

14 October 2017

17 January 2013

1 reference

14 October 2017

1 reference

14 October 2017

73

1 reference

14 October 2017

9

1 reference

14 October 2017

905-912

1 reference

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

Androgen regulation of ETS gene fusion transcripts in prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

Antibody-based detection of ERG rearrangement-positive prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677047

The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening

18 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23334893

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PROS.22636

1 reference

14 October 2017

1 reference

14 October 2017

PubMed publication ID

23334893

1 reference